Ocular Therapeutix (OCUL) Set to Announce Earnings on Monday

Ocular Therapeutix (NASDAQ:OCUL – Get Rating) is scheduled to be announcing its earnings results after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Ocular Therapeutix (NASDAQ:OCUL – Get Rating) last released its quarterly earnings data on Monday, February 28th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.23). The business had revenue of $12.31 million during the quarter, compared to analyst estimates of $14.18 million. Ocular Therapeutix had a negative net margin of 15.06% and a negative return on equity of 7.73%. During the same period last year, the business earned ($0.23) EPS. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of NASDAQ OCUL opened at $3.57 on Monday. The firm’s 50 day moving average price is $4.81 and its 200-day moving average price is $6.02. Ocular Therapeutix has a 52-week low of $3.54 and a 52-week high of $19.65. The company has a current ratio of 7.26, a quick ratio of 7.22 and a debt-to-equity ratio of 0.58.

OCUL has been the topic of a number of research analyst reports. JMP Securities lowered their price target on Ocular Therapeutix from $30.00 to $22.00 and set a “market outperform” rating on the stock in a report on Tuesday, March 1st. Zacks Investment Research cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Tuesday, January 11th. Finally, StockNews.com assumed coverage on shares of Ocular Therapeutix in a research note on Thursday, March 31st. They set a “hold” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $19.40.

In other Ocular Therapeutix news, major shareholder Summer Road Llc purchased 40,000 shares of the company’s stock in a transaction on Friday, February 18th. The stock was acquired at an average cost of $5.00 per share, for a total transaction of $200,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 3.60% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in OCUL. OLD Mission Capital LLC purchased a new stake in shares of Ocular Therapeutix during the third quarter valued at $184,000. Morgan Stanley boosted its holdings in Ocular Therapeutix by 47.1% in the second quarter. Morgan Stanley now owns 491,867 shares of the biopharmaceutical company’s stock worth $6,974,000 after acquiring an additional 157,541 shares in the last quarter. Invesco Ltd. increased its position in shares of Ocular Therapeutix by 20.2% in the 3rd quarter. Invesco Ltd. now owns 106,441 shares of the biopharmaceutical company’s stock valued at $1,064,000 after acquiring an additional 17,923 shares during the period. Royal Bank of Canada raised its stake in shares of Ocular Therapeutix by 4.2% in the third quarter. Royal Bank of Canada now owns 81,277 shares of the biopharmaceutical company’s stock worth $812,000 after purchasing an additional 3,282 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in Ocular Therapeutix by 376.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 13,560 shares of the biopharmaceutical company’s stock valued at $136,000 after acquiring an additional 10,714 shares during the period. 53.94% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile (Get Rating)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Read More